Activity of amlodipine against Staphylococcus aureus: association with oxacillin and mechanism of action

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. WHO publishes list of bacteria for which new antibiotics are urgently needed. www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed
  Google Scholar
• 2. Diekema DJ, Pfaller MA, Shortridge D, Zervos M, Jones RN. Twenty-year trends in antimicrobial susceptibilities among Staphylococcus aureus from the SENTRY Antimicrobial Surveillance Program. Open Forum Infect. Dis. 6(Suppl. 1), S47–S53 (2019).
  MedlineGoogle Scholar
• 3. Horváth A, Dobay O, Sahin-Tóth J et al. Characterisation of antibiotic resistance, virulence, clonality and mortality in MRSA and MSSA bloodstream infections at a tertiary-level hospital in Hungary: a 6-year retrospective study. Ann. Clin. Microbiol. Antimicrob. 19(1), 17 (2020).
  Medline CASGoogle Scholar
• 4. Mama OM, Aspiroz C, Lozano C et al. Penicillin susceptibility among invasive MSSA infections: a multicentre study in 16 Spanish hospitals. J. Antimicrob. Chemother. 76(10), 2519–2527 (2021).
  Medline CASGoogle Scholar
• 5. Rozgonyi F, Kocsis E, Kristóf K, Nagy K. Is MRSA more virulent than MSSA? Clin. Microbiol. Infect. 13(9), 843–845 (2007).
  Medline CASGoogle Scholar
• 6. Lakhundi S, Zhang K. Methicillin-resistant Staphylococcus aureus: molecular characterization, evolution, and epidemiology. Clin. Microbiol. Rev. 31(4), e00020–18 (2018).
  Medline CASGoogle Scholar
• 7. Lister JL, Horswill AR. Staphylococcus aureus biofilms: recent developments in biofilm dispersal. Front. Cell Infect. Microbiol. 4, 178 (2014).
  MedlineGoogle Scholar
• 8. Escolà-Vergé L, Los-Arcos I, Almirante B. New antibiotics for the treatment of infections by multidrug-resistant microorganisms. Med. Clin. (Barc.) 154(9), 351–357 (2020).
  Medline CASGoogle Scholar
• 9. Farha MA, Brown ED. Drug repurposing for antimicrobial discovery. Nat. Microbiol. 4(4), 565–577 (2019).
  Medline CASGoogle Scholar
• 10. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58(3), 621–681 (2006).
  Medline CASGoogle Scholar
• 11. Bulsara KG, Cassagnol M. Amlodipine (2020). www.ncbi.nlm.nih.gov/books/NBK519508/
  Google Scholar
• 12. Homa M, Hegedus K, Fülöp Á et al. In vitro activity of calcium channel blockers in combination with conventional antifungal agents against clinically important filamentous fungi. Acta Biol. Hung. 68(3), 334–344 (2017).
  Medline CASGoogle Scholar
• 13. Liu S, Yue L, Gu W, Li X, Zhang L, Sun S. Synergistic effect of fluconazole and calcium channel blockers against resistant Candida albicans. PLOS ONE 11(3), e015085 (2016).
  Google Scholar
• 14. Mazumdar K, Asok Kumar K, Dutta NK. Potential role of the cardiovascular non-antibiotic (helper compound) amlodipine in the treatment of microbial infections: scope and hope for the future. Int. J. Antimicrob. Agents 36(4), 295–302 (2010). •• According to the authors, amlodipine is the most promising nonantibiotic antimicrobial cardiovascular drug. This study suggested that the doses of amlodipine needed to effectively treat an infection in vivo may be significantly lower than the doses used in vitro to inhibit bacterial growth.
  Medline CASGoogle Scholar
• 15. Kruszewska H, Zareba T, Tyski S. Estimation of antimicrobial activity of selected non-antibiotic products. Acta Pol. Pharm. 63(5), 457–460 (2006).
  Medline CASGoogle Scholar
• 16. M07-A10 Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard - Tenth Edition (2015). https://clsi.org/media/1928/m07ed11_sample.pdf
  Google Scholar
• 17. Batista de Andrade Neto J, Alexandre Josino MA, Rocha da Silva C et al. A mechanistic approach to the in-vitro resistance modulating effects of fluoxetine against meticillin resistant Staphylococcus aureus strains. Microb. Pathog. 127, 335–340 (2019).
  MedlineGoogle Scholar
• 18. Das B, Mandal D, Dash SK et al. Eugenol provokes ROS-mediated membrane damage-associated antibacterial activity against clinically isolated multidrug-resistant Staphylococcus aureus strains. Infect. Dis. 9, PMC4756864 (2016).
  Google Scholar
• 19. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52(1), 1 (2003).
  Medline CASGoogle Scholar
• 20. Jorge P, Grzywacz D, Kamysz W, Lourenço A, Pereira MO. Searching for new strategies against biofilm infections: colistin-AMP combinations against Pseudomonas aeruginosa and Staphylococcus aureus single- and double-species biofilms. PLOS ONE 12(3), e0174654 (2017).
  MedlineGoogle Scholar
• 21. Brambilla LZS, Endo EH, Cortez DAG, Filho BPD. Anti-biofilm activity against Staphylococcus aureus MRSA and MSSA of neolignans and extract of Piper regnellii. Rev. Bras. Farmacogn. 27(1), 112–117 (2017).
  CASGoogle Scholar
• 22. Costa EM, Silva S, Madureira AR, Cardelle-Cobas A, Tavaria FK, Pintado MM. A comprehensive study into the impact of a chitosan mouthwash upon oral microorganism's biofilm formation in vitro. Carbohydr. Polym. 101(1), 1081–1086 (2014).
  Medline CASGoogle Scholar
• 23. Brambilla LZS, Endo EH, Cortez DAG, Filho BPD. Anti-biofilm activity against Staphylococcus aureus MRSA and MSSA of neolignans and extract of Piper regnellii. Rev. Bras. Farmacogn. 27(1), 112–117 (2017).
  CASGoogle Scholar
• 24. do Av Sá LG, da Silva CR, de A Neto JB et al. Etomidate inhibits the growth of MRSA and exhibits synergism with oxacillin. Future Microbiol. 15(17), 1611–1619 (2020).
  Google Scholar
• 25. Silva F, Ferreira S, Queiroz JA, Domingues FC. Coriander (Coriandrum sativum L.) essential oil: its antibacterial activity and mode of action evaluated by flow cytometry. J. Med. Microbiol. 60(Pt 10), 1479–1486 (2011).
  Medline CASGoogle Scholar
• 26. Shi L, Günther S, Hübschmann T, Wick LY, Harms H, Müller S. Limits of propidium iodide as a cell viability indicator for environmental bacteria. Cytometry A 71(8), 592–598 (2007).
  MedlineGoogle Scholar
• 27. Neto JBA, da Silva CR, Nascimento FBSA et al. Screening of antimicrobial metabolite yeast isolates derived biome Ceará against pathogenic bacteria, including MRSA: antibacterial activity and mode of action evaluated by flow cytometry. Int. J. Curr. Microbiol. App. Sci. 4(5), 459–472 (2015).
  CASGoogle Scholar
• 28. Neto JBA, da Silva CR, Neta MAS et al. Antifungal activity of naphthoquinoidal compounds in vitro against fluconazole-resistant strains of different Candida species: a special emphasis on mechanisms of action on Candida tropicalis. PLOS ONE 9(5), e93698 (2014).
  MedlineGoogle Scholar
• 29. Dwyer DJ, Camacho DM, Kohanski MA, Callura JM, Collins JJ. Antibiotic-induced bacterial cell death exhibits physiological and biochemical hallmarks of apoptosis. Mol. Cell 46(5), 561–572 (2012).
  Medline CASGoogle Scholar
• 30. MarvinSketch and MarvinView: Molecule Applets for the World Wide Web. ChemAxon. https://chemaxon.com/presentation/marvinsketch-and-marvinview-molecule-applets-for-the-world-wide-web
  Google Scholar
• 31. Marvin. ChemAxon. https://chemaxon.com/products/marvin
  Google Scholar
• 32. Hanwell MD, Curtis DE, Lonie DC, Vandermeerschd T, Zurek E, Hutchison GR. Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J. Cheminform. 4(8), 1–17 (2012).
  MedlineGoogle Scholar
• 33. Batista de Andrade Neto J, Pessoa de Farias Cabral V, Brito Nogueira LF et al. Anti-MRSA activity of curcumin in planktonic cells and biofilms and determination of possible action mechanisms. Microb. Pathog. 155, 104892 (2021).
  MedlineGoogle Scholar
• 34. Foletti D, Strop P, Shaughnessy L et al. Mechanism of action and in vivo efficacy of a human-derived antibody against Staphylococcus aureus α-hemolysin. J. Mol. Biol. 425(10), 1641–1654 (2013).
  Medline CASGoogle Scholar
• 35. Caballero AR, Foletti DL, Bierdeman MA et al. Effectiveness of alpha-toxin Fab monoclonal antibody therapy in limiting the pathology of Staphylococcus aureus keratitis. Ocul. Immunol. Inflamm. 23(4), 297–303 (2015).
  Medline CASGoogle Scholar
• 36. Yan J, Zhang G, Pan J, Wang Y. α-Glucosidase inhibition by luteolin: kinetics, interaction and molecular docking. Int. J. Biol. Macromol. 64, 213–223 (2014).
  Medline CASGoogle Scholar
• 37. Using AutoDock 4 and AutoDock Vina with AutoDockTools: A Tutorial. https://zdoc.pub/using-autodock-4-and-autodock-vina-with-autodocktools-a-tuto.html
  Google Scholar
• 38. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J. Comput. Chem. 31(2), 455 (2010).
  Medline CASGoogle Scholar
• 39. Marinho EM, Batista de Andrade Neto J, Silva J et al. Virtual screening based on molecular docking of possible inhibitors of COVID-19 main protease. Microb. Pathog. 148, 104365 (2020).
  Medline CASGoogle Scholar
• 40. BIOVIA Discovery Studio–BIOVIA–Dassault Systèmes^®. www.3ds.com/products-services/biovia/products/molecular-modeling-simulation/biovia-discovery-studio/
  Google Scholar
• 41. Pettersen EF, Goddard TD, Huang CC et al. UCSF Chimera–a visualization system for exploratory research and analysis. J. Comput. Chem. 25(13), 1605–1612 (2004).
  Medline CASGoogle Scholar
• 42. Yusuf D, Davis AM, Kleywegt GJ, Schmitt S. An alternative method for the evaluation of docking performance: RSR vs RMSD. J. Chem. Inf. Model 48(7), 1411–1422 (2008).
  Medline CASGoogle Scholar
• 43. Shityakov S, Förster C. In silico predictive model to determine vector-mediated transport properties for the blood-brain barrier choline transporter. Adv. Appl. Bioinform. Chem. 7(1), 23 (2014).
  MedlineGoogle Scholar
• 44. Imberty A, Hardman KD, Carver JP, Perez S. Molecular modelling of protein-carbohydrate interactions. Docking of monosaccharides in the binding site of concanavalin A. Glycobiology 1(6), 631–642 (1991).
  Medline CASGoogle Scholar
• 45. Berdigaliyev N, Aljofan M. An overview of drug discovery and development. Future Med. Chem. 12(10), 939–947 (2020).
  Medline CASGoogle Scholar
• 46. VanZwieten PA.Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties.17(9 Suppl. 3), III3–III6 (1994). https://pubmed.ncbi.nlm.nih.gov/9156957/
  Google Scholar
• 47. Kim BH, Kim JR, Kim MG et al. Pharmacodynamic (hemodynamic) and pharmacokinetic comparisons of S-amlodipine gentisate and racemate amlodipine besylate in healthy Korean male volunteers: two double-blind, randomized, two-period, two-treatment, two-sequence, double-dummy, single-dose crossover studies. Clin. Ther. 32(1), 193–205 (2010).
  Medline CASGoogle Scholar
• 48. Boyd NK, Lee GC, Teng C, Frei CR. In vitro activity of non-antibiotic drugs against Staphylococcus aureus clinical strains. J. Glob. Antimicrob. Resist. 27, 167–171 (2021). •• Boyd et al. evaluate the minimum inhibitory and bactericidal concentrations of amlodipine against clinical strains of S. aureus and discuss the only metric for evaluating adequate drug exposure in a treatment.
  Medline CASGoogle Scholar
• 49. Wang Y, Li X, Wang D, Sun S, Lu C. In vitro interactions of ambroxol hydrochloride or amlodipine in combination with antibacterial agents against carbapenem-resistant Acinetobacter baumannii. Lett. Appl. Microbiol. 70(3), 189–195 (2020).
  Medline CASGoogle Scholar
• 50. Yi Z. Evaluation of amlodipine inhibition and antimicrobial effects. Int. J. Pharm. Chem. 5(1), 12 (2019). • Yi shows, from enzymatic assays and bacterial tests, that amlodipine may serve as an auxiliary drug, considering that one of the mechanisms presented is the inhibition of β-lactamase, showing the synergistic activity of amlodipine with other beta-lactams.
  CASGoogle Scholar
• 51. Morales G, Paredes A, Sierra P, Loyola LA. Antimicrobial activity of three Baccharis species used in the traditional medicine of Northern Chile. Molecules 13(4), 790 (2008).
  Medline CASGoogle Scholar
• 52. Oyama T, Miyazaki M, Yoshimura M, Takata T, Ohjimi H, Jimi S. Biofilm-forming methicillin-resistant Staphylococcus aureus survive in Kupffer cells and exhibit high virulence in mice. Toxins (Basel) 8(7), 198 (2016).
  MedlineGoogle Scholar
• 53. Gupta P, Chanda R, Rai N, Kataria VK, Kumar N. Antihypertensive, amlodipine besilate inhibits growth and biofilm of human fungal pathogen Candida. Assay Drug Dev. Technol. 14(5), 291–297 (2016).
  Medline CASGoogle Scholar
• 54. Elkhatib WF, Haynes VL, Noreddin AM. Microbiological appraisal of levofloxacin activity against Pseudomonas aeruginosa biofilm in combination with different calcium channel blockers in vitro. J. Chemother. 21(2), 135–143 (2009).
  Medline CASGoogle Scholar
• 55. Pallen MJ. Time to recognise that mitochondria are bacteria? Trends Microbiol. 19(2), 58–64 (2011).
  Medline CASGoogle Scholar
• 56. Levine C, Hiasa H, Marians KJ. DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim. Biophys. Acta 1400(1–3), 29–43 (1998).
  Medline CASGoogle Scholar
• 57. Fàbrega A, Madurga S, Giralt E, Vila J. Mechanism of action of and resistance to quinolones. Microb. Biotechnol. 2(1), 40 (2009).
  Medline CASGoogle Scholar
• 58. Elkhatib WF, Haynes VL, Noreddin AM. Microbiological appraisal of levofloxacin activity against Pseudomonas aeruginosa biofilm in combination with different calcium channel blockers in vitro. J. Chemother. 21(2), 135–143 (2013).
  Google Scholar